Primary Myelofibrosis News and Research

RSS
YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

Retrospective study demonstrates new survival data for patients with myelofibrosis

Retrospective study demonstrates new survival data for patients with myelofibrosis

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

New treatment options for leukemia and myeloproliferative disorders introduced

New treatment options for leukemia and myeloproliferative disorders introduced

Discovery of mutant genes in acute lymphoblastic leukemia

Discovery of mutant genes in acute lymphoblastic leukemia

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Experimental drug successfully blocks mutation in bone marrow cancers

Experimental drug successfully blocks mutation in bone marrow cancers

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Anemia drugs linked with leukemic transformation in patients with primary myelofibrosis

Anemia drugs linked with leukemic transformation in patients with primary myelofibrosis